Impax, Teva reach settlement with J&J over ADHD drug
Sept 14 (Reuters) - Impax Laboratories Inc and Israel's Teva Pharmaceutical Industries Ltd settled a two-year patent dispute with Johnson & Johnson, allowing the generic drugmakers to start selling a copy of Johnson & Johnson's ADHD drug from July 14, 2013.
In 2010, J&J unit Alza filed a lawsuit to block Impax from launching a copy of Alza's Concerta extended-release tablets that treat attention deficit hyperactivity disorder.
According to Wolters Kluwer Health, U.S. brand and generic sales of Concerta were about $1.2 billion for the 12 months ended July 2012, Impax said in a statement.
The Concerta products are part of Impax's 2001 strategic alliance agreement with Teva. Teva has already filed with U.S. regulators to get approval for a generic version of the drug.
Under the settlement, Alza has agreed to give Impax and Teva a license to sell generic versions of Concerta on July 14, 2013, or earlier under certain circumstances, Impax said.
- Insight: How U.S. spying cost Boeing multibillion-dollar jet contract
- Exclusive: Secret contract tied NSA and security industry pioneer |
- With Fed out of the way, what's next on Wall Street?
- Yemeni al Qaeda says attack on hospital was mistake
- Insight: For Chinese farmers, a rare welcome in Russia's Far East